• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Michael Fitzhugh

Articles by Michael Fitzhugh

‘Array’ narrowed: Selumetinib NSCLC trial fail de-SELECTs indication

Aug. 10, 2016
By Michael Fitzhugh
Hopes that MEK inhibitor selumetinib might rise above an earlier failure to improve a rare eye cancer were dashed as the Astrazeneca plc-backed candidate fell short of improving progression-free survival during SELECT-1, a phase III trial targeting NSCLC.
Read More

Wrangling the right talent to tackle big data can be tough

Aug. 9, 2016
By Michael Fitzhugh
The NIH has a serious problem, and it's not alone. Even as big datasets driving new threads of biomedical progress proliferate, a critical shortfall is showing up in another realm: "There is a desperate need for individuals who can develop creative approaches to bioinformatics problems." the NIH told members of the National Science and Technology Council last year.
Read More

Cleave lands $37M series B financing

Aug. 9, 2016
By Michael Fitzhugh
Cleave Biosciences Inc. has completed a $37 million series B financing to support further development of CB-5083, its lead oncology candidate for hematological and solid tumor malignancies and discovery efforts related to its AAA ATPase platform over the next 18 months.
Read More

Big data's big challenges with drug discovery

Aug. 8, 2016
By Michael Fitzhugh

Big data's big challenges in drug discovery

Aug. 8, 2016
By Michael Fitzhugh
Given the blistering rate at which researchers of all stripes, academic and corporate, are accumulating data on the molecular nature of disease, applying those data in drug discovery efforts is a natural next step. But, even with plentiful data and computing power, multiple roadblocks to reducing the time, costs and productivity of discovery remain.
Read More

Hedgepath sows seeds of itraconazole-based anticancer program

Aug. 4, 2016
By Michael Fitzhugh
Interim results from a phase IIb trial testing a proprietary formulation of the anti-fungal drug itraconazole for the treatment of Gorlin syndrome reduced tumor burden by more than 30 percent in eight of 13 patients, Hedgepath Pharmaceuticals Inc. reported.
Read More

Advaxis, Amgen strike $540M preclinical-stage immunotherapy alliance; $40M cash up front

Aug. 3, 2016
By Michael Fitzhugh
Global rights to Advaxis Inc.’s preclinical cancer immunotherapy, ADXS-NEO, are going to Amgen Inc. for a combined pledge of up to $540 million, giving Advaxis new cash to fuel its FDA fast-tracked phase III cervical cancer treatment, AXAL, while feeding Amgen’s ongoing interest in cancer vaccines, a pursuit that led to approval of the first FDA-approved oncolytic virus therapy, Imlygic (talimogene laherparepvec), last October.
Read More

Manufacturing issues snag BLA for Adma's lead candidate

Aug. 2, 2016
By Michael Fitzhugh
Inspection issues and deficiencies at contract manufacturers for Adma Biologics Inc.'s primary immunodeficiency treatment RI-002 drew an FDA complete response letter for the company's biologics license application, sending Adma shares (NASDAQ:ADMA) down 17.3 percent to close at $6.49 on Monday.
Read More

Jazz inks $181M blood cancer deal with Pfenex

Aug. 1, 2016
By Michael Fitzhugh
Jazz Pharmaceuticals plc licensed global rights to several early stage blood cancer candidates from Pfenex Inc. in a deal that also included an option on an exclusive license for PF690, a biosimilar of Baxalta Inc.'s acute lymphoblastic leukemia (ALL) therapy, Oncaspar (pegaspargase), access to which could give Jazz wider reach in ALL.
Read More

Wrangling the right talent to tackle big data can be tough

Aug. 1, 2016
By Michael Fitzhugh
The NIH has a serious problem, and it's not alone. Even as big datasets driving new threads of biomedical progress proliferate, a critical shortfall is showing up in another realm: "There is a desperate need for individuals who can develop creative approaches to bioinformatics problems." the NIH told members of the National Science and Technology Council last year.
Read More
Previous 1 2 … 126 127 128 129 130 131 132 133 134 … 179 180 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 8, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 8, 2025.
  • U.S. Capitol building, Washington D.C.

    House passes H.R. 1, restoring R&D tax cuts

    BioWorld MedTech
    The House of Representatives passed H.R. 1, also known as One Big Beautiful Bill, which will restore personal income tax cuts that expired in 2022. However, the...
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • 3D rendering of a molecular glue mediating the interaction between two proteins

    With surface mimicry, molecular glues shed hairpin need

    BioWorld Science
    Degradation is a therapeutic strategy that could offer possibilities to get at currently undruggable target proteins. In targeted degradation, compounds induce...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe